Stoke Therapeutics (STOK)
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
📈 **POSITIVE** • High confidence analysis (89%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business